The Gurugram-based healthcare provider recently rebounded from early session dips to reach a record ₹777 on the BSE following its initial public offering. Choice Institutional Equities initiated coverage with a "Buy" recommendation and a ₹900 price target, citing a projected 30% upside. The firm's six core medical specialties, including oncology and cardiac sciences, generated roughly 75% of its FY26 revenue. Future performance will also be supported by India's broader healthcare delivery market, which is anticipated to reach up to ₹12.2 lakh crore by FY30.
Key points
The hospital chain currently operates eight healthcare facilities located across five Ind…: The hospital chain currently operates eight healthcare facilities located across five Indian states and one Union Territory.
Six core clinical specialties account for approximately 75% of the provider's total reven…: Six core clinical specialties account for approximately 75% of the provider's total revenue for FY26.
Long-term valuation gains remain tied to the operator's ability to scale hospital bed cap…: Long-term valuation gains remain tied to the operator's ability to scale hospital bed capacity and lift operating margins.
Sources checked by our analysis pipeline: 1
Paras Healthcare shares fell by over 2% in early trade on Thursday, October 29, following a decent stock market debut the day before. However, the stock rebounded sharply, rising 5.4% to a record high of ₹777 per share on the BSE.
Paras Healthcare share price today opened at an intraday low of ₹719.75 per share, and touched an intraday high of ₹777 apiece.
On Wednesday, the stock ended at ₹737.15 on the BSE, up 6.37% from the issue price. On the NSE, it closed at ₹735.60, up 6.14%. The stock listed at ₹720 on the BSE and NSE, a 3.89% premium over its IPO price of ₹693 per share.
The initial public offering (IPO) of Paras Healthcare was subscribed 2.23 times on the final day of bidding last Friday. The company had set the price band at ₹660– ₹693 per share.
The ₹1,450 crore IPO comprised a fresh issue of equity shares worth ₹500 crore and an offer for sale (OFS) of ₹950 crore by promoter Dharminder Kumar Nagar and investor Commelina Ltd.
The latest quarterly financial filings reveal sharply diverging momentum between two of India's largest consumer goods majors amid rising commodity pressures. While faster percentage expansion powered one firm's bottom line, the other leveraged immense operational scale to outpace revenue targets and return cash directly to shareholders. These contrasting operational margins and payout strategies have left leading brokerages cautious regarding near-term sector valuations.
Strong operational showings across core mining operations have propelled substantial profit gains and significant debt reduction for the conglomerate's primary entities. Analysts are pointing to the parent company's heavy reliance on subsidiary earnings as a major driver for ongoing corporate strength. Meanwhile, specific trading parameters have been established for emerging demerged businesses to capture further upside.
Disappointing earnings and valuation worries across the artificial intelligence sector triggered severe declines across mainland exchanges. A widely anticipated interest rate pause by the U.S. Federal Reserve did little to calm nerves, as persistent inflation keeps borrowing costs high. Investors are increasingly questioning whether aggressive AI spending can continue to generate sufficient earnings growth.